Date Release

 December 9

SABRIL® (vigabatrin) Vision Data Presented in Two Late-Breaking Posters at American Epilepsy Society Annual Meeting

 November 19

New Initiative Convenes National, Local Leaders to Highlight Community-Oriented Approaches that Aim to Support People with Serious Mental Illness

 November 14

Nationwide Initiative Aims to Help People Living with Epilepsy Manage Seizures and Stay Safe

 November 12

Lundbeck Launches Fourth Annual Build Hope for Huntington’s Disease Campaign in partnership with the Hereditary Disease Foundation

 November 1

New Online Community Connects People Affected by Challenging Seizure Disorder

 October 28

SABRIL® (vigabatrin) Now FDA Approved as an Adjunctive Treatment Option for Children 10 and older with Refractory Complex Partial Seizures

 October 16

New Program Connects Parents of Children with Infantile Spasms to Others Who Have Experience with SABRIL® (vigabatrin)                

 October 10

Lundbeck and Otsuka Announce Initiation of Phase 3 Clinical Trials for Alzheimer’s Compound

 September 30

Takeda and Lundbeck Announce FDA Approval of BrintellixTM (vortioxetine) for Treatment of Adults with Major Depressive Disorder

 August 29

Lundbeck Epilepsy Research Featured in Report on Neurological Disorders

 August 12

ONFI® (clobazam) CIV Scored Tablets and Oral Suspension Now Available in U.S. Pharmacies

July 16

Phase II clinical data show statistically significant improvement for Lu AE58054 as add-on to donepezil, versus donepezil alone, on cognitive symptoms of Alzheimer’s disease

May 21

Study Shows Effects Of Treatment With Abilify Maintena™ (Aripiprazole) On Psychiatric Hospitalization Rates For Patients With Schizophrenia

May 18

Takeda and Lundbeck Present Results from Pivotal Phase 3 Clinical Trials with Vortioxetine, an Investigational Compound for Major Depressive Disorder

February 28

FDA Approves Once-Monthly Abilify Maintena™ (aripiprazole) for Extended-Release Injectable Suspension for the Treatment of Schizophrenia

February 4

Raise Your Hand with Lundbeck and NORD to Support Rare Disease Awareness and Research

January 23

Lennox-Gastaut Syndrome Foundation and Lundbeck Announce Scholarship

Contact Us


Ashleigh Duchene
Associate Director, Public Relations
Email: ADUC@lundbeck.com
Phone: 312-802-2906


Rachel Vann
Senior Manager, Public Relations
Email: RVAN@lundbeck.com
Phone: 224-507-8401

Follow us on Twitter!

Get our latest company news.

Click here
You have chosen to visit another Lundbeck website or a third-party website, which is provided as a service to you. Lundbeck does not control content on third-party websites and cannot make representations concerning the accuracy of information on every website you visit. Lundbeck is not responsible for the privacy policy of any third-party website. We encourage you to read the privacy policy of every website you visit. Click OK to continue or Cancel to return to Lundbeck.